[go: up one dir, main page]

DK1910529T3 - Polynukleotider, der koder for HLA-B7-begrænsede hTERT-epitoper til anvendelse ved forebyggelse og/eller behandling af cancer - Google Patents

Polynukleotider, der koder for HLA-B7-begrænsede hTERT-epitoper til anvendelse ved forebyggelse og/eller behandling af cancer

Info

Publication number
DK1910529T3
DK1910529T3 DK06762910.5T DK06762910T DK1910529T3 DK 1910529 T3 DK1910529 T3 DK 1910529T3 DK 06762910 T DK06762910 T DK 06762910T DK 1910529 T3 DK1910529 T3 DK 1910529T3
Authority
DK
Denmark
Prior art keywords
treatment
polynucleotides encoding
cancer prevention
encoding hla
restricted htert
Prior art date
Application number
DK06762910.5T
Other languages
English (en)
Inventor
Pierre Langlade-Demoyen
Pons Francisco Garcia
Olivier Adotevi
Sylvain Cardinaud
Christine Neuveut
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1910529T3 publication Critical patent/DK1910529T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06762910.5T 2005-07-29 2006-07-31 Polynukleotider, der koder for HLA-B7-begrænsede hTERT-epitoper til anvendelse ved forebyggelse og/eller behandling af cancer DK1910529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291627A EP1748067A1 (en) 2005-07-29 2005-07-29 Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
PCT/EP2006/007571 WO2007014740A2 (en) 2005-07-29 2006-07-31 Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes

Publications (1)

Publication Number Publication Date
DK1910529T3 true DK1910529T3 (da) 2014-01-13

Family

ID=35735256

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13165854.4T DK2626420T3 (da) 2005-07-29 2006-07-31 Polynukleotider, der koder for MHC klasse I HLA-B7-begrænsede HTERT-epitoper, analoger deraf eller polyepitoper
DK06762910.5T DK1910529T3 (da) 2005-07-29 2006-07-31 Polynukleotider, der koder for HLA-B7-begrænsede hTERT-epitoper til anvendelse ved forebyggelse og/eller behandling af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13165854.4T DK2626420T3 (da) 2005-07-29 2006-07-31 Polynukleotider, der koder for MHC klasse I HLA-B7-begrænsede HTERT-epitoper, analoger deraf eller polyepitoper

Country Status (9)

Country Link
US (3) US8858931B2 (da)
EP (3) EP1748067A1 (da)
JP (4) JP5631545B2 (da)
CA (1) CA2616674C (da)
DK (2) DK2626420T3 (da)
ES (2) ES2440768T3 (da)
PL (1) PL2626420T3 (da)
PT (1) PT2626420T (da)
WO (1) WO2007014740A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2008010010A1 (en) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
JP5596980B2 (ja) * 2007-02-28 2014-10-01 アメリカ合衆国 ブラキュリポリペプチドおよび使用方法
PL2562184T3 (pl) * 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
US7904566B2 (en) * 2008-03-14 2011-03-08 Silicon Image, Inc. Method, apparatus, and system for employing an enhanced port multiplier
US7979589B2 (en) * 2008-03-14 2011-07-12 Silicon Image, Inc. Method, apparatus, and system for port multiplier enhancement
CN108383894A (zh) 2010-02-16 2018-08-10 阿尔特公司 多肽及其应用
JP2015509974A (ja) 2012-03-15 2015-04-02 マクロキュア，リミテッド 感染治療のための活性化された免疫刺激細胞組成物
CA2865553A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CN107312759B (zh) * 2012-09-19 2025-10-28 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
WO2014105870A1 (en) 2012-12-27 2014-07-03 Sierra Sciences, Inc. Enhancing health in mammals using telomerase reverse transcriptase gene therapy
US10138488B2 (en) 2013-03-28 2018-11-27 Invectys Cancer vaccine for dogs
AU2014242915B2 (en) * 2013-03-28 2018-08-09 Invectys A cancer vaccine for cats
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
PT3062824T (pt) * 2013-10-28 2020-02-21 Invectys Vacina de adn de codificação da telomerase
EA035485B1 (ru) 2013-10-28 2020-06-24 Инвектис Электроперенос генов в клетки кожи
HK1245134A1 (zh) 2015-01-14 2018-08-24 The Brigham And Women's Hospital, Inc. 用抗lap单克隆抗体治疗癌症
EP3268012A4 (en) 2015-03-12 2018-10-31 Health Research, Inc. Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
ES2809508T3 (es) * 2015-10-06 2021-03-04 Invectys Estructuras artificiales de poliepítopos para uso en inmunoterapia
GB201519557D0 (en) 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
JP7781511B2 (ja) * 2016-09-30 2025-12-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
CA3086923A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
CN110305217B (zh) 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
US12144851B2 (en) 2018-04-13 2024-11-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccinal strategy
MX2021002333A (es) * 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
CN113105528B (zh) * 2020-01-13 2023-12-08 辽宁中健医药科技有限公司 一条肿瘤相关抗原ctl表位肽及其应用
AU2021294322A1 (en) * 2020-06-26 2023-02-02 National Breast Cancer Coalition Breast cancer vaccine
CN118792176A (zh) * 2024-07-24 2024-10-18 佳吾益(北京)科技有限公司 用于mhc新抗原肽发现及亲和分析的工程化细胞

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129222A0 (en) * 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
JP2002514928A (ja) * 1997-07-01 2002-05-21 キャンビア バイオシステムス リミティド ライアビリティー カンパニー 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
ATE449858T1 (de) 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
AU784910B2 (en) 1999-10-12 2006-07-27 Centre National De La Recherche Scientifique Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2862648B1 (fr) * 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Also Published As

Publication number Publication date
US8858931B2 (en) 2014-10-14
JP5931812B2 (ja) 2016-06-08
JP2009502150A (ja) 2009-01-29
JP2012183076A (ja) 2012-09-27
EP2626420B1 (en) 2016-06-22
EP2626420A3 (en) 2013-10-30
EP2626420A2 (en) 2013-08-14
PT2626420T (pt) 2016-09-28
JP5836202B2 (ja) 2015-12-24
WO2007014740A3 (en) 2007-05-03
PL2626420T3 (pl) 2017-01-31
EP1910529A2 (en) 2008-04-16
EP1748067A1 (en) 2007-01-31
US20090175892A1 (en) 2009-07-09
ES2440768T3 (es) 2014-01-30
US9624479B2 (en) 2017-04-18
EP1910529B1 (en) 2013-10-16
CA2616674C (en) 2018-09-04
US20140056932A1 (en) 2014-02-27
JP2013230164A (ja) 2013-11-14
US20100172878A1 (en) 2010-07-08
WO2007014740A2 (en) 2007-02-08
US8003773B2 (en) 2011-08-23
JP2016104031A (ja) 2016-06-09
CA2616674A1 (en) 2007-02-08
ES2590462T3 (es) 2016-11-22
DK2626420T3 (da) 2016-09-26
JP5631545B2 (ja) 2014-11-26
JP6257667B2 (ja) 2018-01-10

Similar Documents

Publication Publication Date Title
DK1910529T3 (da) Polynukleotider, der koder for HLA-B7-begrænsede hTERT-epitoper til anvendelse ved forebyggelse og/eller behandling af cancer
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DK1749098T3 (da) Kimære adenoviruser til anvendelse i carcerbehandling
DK2100614T3 (da) Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
DK2032701T3 (da) Polynukleotider og polypeptider, der er inddraget i cancer
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2205257T3 (da) Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
DK1943016T3 (da) Kompositnanopartikler, nanopartikler og fremgangsmåder til fremstilling heraf
DK2152676T3 (da) Triazinderivater, sammensætninger, der indeholder sådanne derivater, og fremgangsmåde til behandling af cancer og autoimmunsygdomme ved anvendelse af sådanne derivater
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
PT1844337E (pt) Compostos ligantes, compostos imunogénicos e peptidomiméticos
DK2152794T3 (da) Oxygen-fjernende molekyler, artikler indeholdende disse, og fremgangsmåde til deres anvendelse
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
PL1715259T3 (pl) Ogrzewana pompa z zabezpieczeniem przed gotowaniem
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
GB0507587D0 (en) Facilitating and authenticating transactions
DK1960370T3 (da) Pyridazinonderivater til tumorbehandling
FI20050770L (fi) Todentaminen turvakäytännön yhteydessä
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK3067068T3 (da) Natrium-meta-arsenit til anvendelse i behandlingen af myelomatose
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK1896571T3 (da) Materialer og fremgangsmåder, der vedrører cellebaserede behandlinger
DK2061807T3 (da) MHC-oligomerer, bestanddele deraf og fremgangsmåder til fremstilling deraf
TWI346493B (en) User authentication using personal objects